PharmGKB summary: Very important pharmacogene information for N-acetyltransferase 2

Pharmacogenetics and Genomics

Volumn 24, Issue 8, 2014, Pages 409-425

  McDonagh, Ellen M ^a   Boukouvala, Sotiria ^c   Aklillu, Eleni ^d   Hein, David W ^b   Altman, Russ B ^a   Klein, Teri E ^a  

^a STANFORD UNIVERSITY   (United States)

^b University of Louisville School of Medicine   (United States)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

acetylation; acetylator; drug toxicity; genotype; metabolism; N acetyltransferase 1; N acetyltransferase 2; pharmacogenetics; pharmacokinetics

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; HYDRALAZINE; ISONIAZID; N ACETYLTRANSFERASE 1; SALAZOSULFAPYRIDINE; SULFAMETHOXAZOLE; UNCLASSIFIED DRUG;

ACETYLATION; ALLELE; ARTICLE; CANCER RESISTANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMICAL CARCINOGENESIS; COMPLEMENT SYSTEM; DNA METHYLATION; DRUG CLEARANCE; DRUG EXPOSURE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE CONTROL; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOMICS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PAIN; PHARMACOGENETICS; PHARMACOKINETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SMOKING; TREATMENT RESPONSE;

ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; GENE EXPRESSION PROFILING; GENOMICS; GENOTYPE; HUMANS; HYDRALAZINE; ISOENZYMES; ISONIAZID; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; SULFAMETHOXAZOLE; SULFASALAZINE; XENOBIOTICS;

EID: 84904397825     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000062     Document Type: Article

References (210)

1. International Union of Biochemistry and Molecular Biology (IUBMB) Nomenclature Committee. Recommendations for Enzyme Nomenclature. Available at: http://www.chem.qmul.ac.uk/iubmb/enzyme/. [Accessed 13 August 2013].
2. Hein DW. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol 2009; 5:353-366.
3. Stanley LA, Sim E. Update on the pharmacogenetics of NATs: structural considerations. Pharmacogenomics 2008; 9:1673-1693.
4. Sim E, Fakis G, Laurieri N, Boukouvala S. Arylamine N-acetyltransferases- from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention. Adv Pharmacol 2012; 63:169-205.
5. Sim E, Lack N, Wang CJ, Long H, Westwood I, Fullam E, Kawamura A. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 2008; 254:170-183.
6. Sabbagh A, Marin J, Veyssiere C, Lecompte E, Boukouvala S, Poloni ES, et al. Rapid birth-and-death evolution of the xenobiotic metabolizing NAT gene family in vertebrates with evidence of adaptive selection. BMC Evol Biol 2013; 13:62.
7. Sim E, Abuhammad A, Ryan A. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol 2014; 171:2705-2725.
8. Butcher NJ, Tiang J, Minchin RF. Regulation of arylamine N-acetyltransferases. Curr Drug Metab 2008; 9:498-504.
9. Grant DM. Structures of human arylamine N-acetyltransferases. Curr Drug Metab 2008; 9:465-470.
10. Kohalmy K, Vrzal R. Regulation of phase II biotransformation enzymes by steroid hormones. Curr Drug Metab 2011; 12:104-123.
11. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, Butcher NJ. Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 2007; 39:1999-2005.
12. Butcher NJ, Minchin RF. Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev 2012; 64:147-165.
13. Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW. Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 2007; 35:721-727.
14. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990; 9:193-203.
15. Hickman D, Risch A, Buckle V, Spurr NK, Jeremiah SJ, McCarthy A, Sim E. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994; 297 (Pt 3):441-445.
16. Butcher NJ, Arulpragasam A, Goh HL, Davey T, Minchin RF. Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities. Biochem J 2005; 387:119-127.
17. Boukouvala S, Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol 2005; 96:343-351.
18. Husain A, Barker DF, States JC, Doll MA, Hein DW. Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 2004; 14:397-406.
19. Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun 1991; 177:1252-1257.
20. National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. NCBI Gene ID: 9 (NAT1). Available at: http://www. ncbi.nlm.nih.gov/gene/9. [Accessed 13 August 2013].
21. National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. NCBI Gene ID: 10 (NAT2). Available at: http://www. ncbi.nlm.nih.gov/gene/10 [Accessed 13 August 2013].
22. Wu H, Dombrovsky L, Tempel W, Martin F, Loppnau P, Goodfellow GH, et al. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J Biol Chem 2007; 282:30189-30197.
23. Arylamine N-acetyltransferase Gene Nomenclature Committee. Available at: http://nat.mbg.duth.gr/. [Accessed 13 August 2013].
24. Hein DW, Boukouvala S, Grant DM, Minchin RF, Sim E. Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics 2008; 18:367-368.
25. Arylamine N-acetyltransferase Gene Nomenclature Committee. Background. Available at: http://nat.mbg.duth.gr/background-2013.html. [Accessed 13 August 2013].
26. Current NAT1 alleles, Arylamine N-acetyltransferase Gene Nomenclature Committee. Available at: http://nat.mbg.duth.gr/Human NAT1 alleles-2013.htm. [Accessed 23 July 2013].
27. Patin E, Barreiro LB, Sabeti PC, Austerlitz F, Luca F, Sajantila A, et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 2006; 78:423-436.
28. Mortensen HM, Froment A, Lema G, Bodo JM, Ibrahim M, Nyambo TB, et al. Characterization of genetic variation and natural selection at the arylamine N-acetyltransferase genes in global human populations. Pharmacogenomics 2011; 12:1545-1558.
29. Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet 2011; 20:528-540.
30. Walraven JM, Zang Y, Trent JO, Hein DW. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 2008; 9:471-486.
31. Soejima M, Sugiura T, Kawaguchi Y, Kawamoto M, Katsumata Y, Takagi K, et al. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther 2007; 9:R23.
32. Ruiz JD, Martínez C, Anderson K, Gross M, Lang NP, García-Martin E, Agúndez JA. The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PLoS One 2012; 7:e44629.
33. Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995; 55:3531-3536.
34. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Müller A, Roots I. Arylamine N-acetyltransferase activity in man. Drug Metab Rev 1999; 31:489-502.
35. Selinski S, Blaszkewicz M, Ickstadt K, Hengstler JG, Golka K. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk. Arch Toxicol 2013; 87:2129-2139.
36. Evans DA. An improved and simplified method of detecting the acetylator phenotype. J Med Genet 1969; 6:405-407.
37. Miller ME, Garland WA, Min BH, Ludwick BT, Ballard RH, Levy RH. Clonazepam acetylation in fast and slow acetylators. Clin Pharmacol Ther 1981; 30:343-347.
38. Marsden JR, Mason GG, Coburn PR, Rawlins MD, Shuster S. Drug acetylation and expression of lupus erythematosus. Eur J Clin Pharmacol 1985; 28:387-390.
39. Grant DM, Mörike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990; 85:968-972.
40. Kagaya H, Miura M, Niioka T, Saito M, Numakura K, Habuchi T, Satoh S. Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. Antimicrob Agents Chemother 2012; 56:825-829.
41. Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol 2013; 28:1368-1374.
42. Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics 2012; 13:31-41.
43. Suarez-Kurtz G, Vargens DD, Sortica VA, Hutz MH. Accuracy of NAT2 SNP genotyping panels to infer acetylator phenotypes in African, Asian, Amerindian and admixed populations. Pharmacogenomics 2012; 13:851-854, author reply 855.
44. Hein DW, Doll MA. A four-SNP NAT2 genotyping panel recommended to infer human acetylator phenotype. Pharmacogenomics 2012; 13:31-41.
45. Zang Y, Doll MA, Zhao S, States JC, Hein DW. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 2007; 28:1665-1671.
46. Rajasekaran M, Abirami S, Chen C. Effects of single nucleotide polymorphisms on human N-acetyltransferase 2 structure and dynamics by molecular dynamics simulation. PLoS One 2011; 6:e25801.
47. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008; 64:673-681.
48. Olivera M, Martinez C, Gervasini G, Carrillo JA, Ramos S, Benítez J, et al. Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett 2007; 1:3-5.
49. Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009; 10:1767-1779.
50. Ben Mahmoud L, Ghozzi H, Kamoun A, Hakim A, Hachicha H, Hammami S, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathol Biol (Paris) 2012; 60:324-330.
51. Bozok Cetinta? V, Erer OF, Kosova B, Ozdemir I, Topçuo?lu N, Akto?u S, Ero?lu Z. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks 2008; 56:81-86.
52. An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 2012; 39:535-543.
53. Taylor KC, Small CM, Dominguez CE, Murray LE, Tang W, Wilson MM, et al. Alcohol, smoking, and caffeine in relation to fecundability, with effect modification by NAT2. Ann Epidemiol 2011; 21:864-872.
54. Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010; 14:622-626.
55. Cramer JP, Lohse AW, Burchard GD, Fischer L, Nashan B, Zimmermann M, et al. Low N-acetyltransferase 2 activity in isoniazidassociated acute hepatitis requiring liver transplantation. Transpl Int 2010; 23:231-233.
56. Diaz-Molina R, Cornejo-Bravo JM, Ramos-Ibarra MA, Estrada-Guzman JD, Morales-Arango O, Reyes-Báez R, et al. Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazid-based prophylactic chemotherapy for tuberculosis. Mol Med Rep 2008; 1:875-879.
57. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001; 16:1033-1037.
58. Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 2010; 10:191-199.
59. Bolt HM, Selinski S, Dannappel D, Blaszkewicz M, Golka K. Reinvestigation of the concordance of human NAT2 phenotypes and genotypes. Arch Toxicol 2005; 79:196-200.
60. García-Closas M, Hein DW, Silverman D, Malats N, Yeager M, Jacobs K, et al. A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics 2011; 21:231-236.
61. Ho HT, Wang TH, Hsiong CH, Perng WC, Wang NC, Huang TY, et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics 2013; 23:200-207.
62. Kim JM, Park BL, Park SM, Lee SH, Kim MO, Jung S, et al. Association analysis of N-acetyl transferase-2 polymorphisms with aspirin intolerance among asthmatics. Pharmacogenomics 2010; 11:951-958.
63. Sabbagh A, Langaney A, Darlu P, Gérard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 2008; 9:21.
64. Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26:312-318.
65. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37:924-930.
66. Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In vivo 2011; 25:803-812.
67. Patin E, Harmant C, Kidd KK, Kidd J, Froment A, Mehdi SQ, et al. Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat 2006; 27:720.
68. Magalon H, Patin E, Austerlitz F, Hegay T, Aldashev A, Quintana-Murci L, Heyer E. Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. Eur J Hum Genet 2008; 16:243-251.
69. Luca F, Bubba G, Basile M, Brdicka R, Michalodimitrakis E, Rickards O, et al. Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS One 2008; 3:e3136.
70. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One 2011; 6:e18507.
71. Khan N, Pande V, Das A. NAT2 sequence polymorphisms and acetylation profiles in Indians. Pharmacogenomics 2013; 14:289-303.
72. Zhu Y, Hein DW. Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenomics J 2008; 8:339-348.
73. Rodrigues-Lima F, Dairou J, Dupret JM. Effect of environmental substances on the activity of arylamine N-acetyltransferases. Curr Drug Metab 2008; 9:505-509.
74. García-Martín E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 2008; 9:487-497.
75. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5:231-249.
76. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise upto-date review. J Gastroenterol Hepatol 2008; 23:192-202.
77. Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab 2007; 8:839-851.
78. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011; 89:911-914.
79. Mahapatra S, Woolhiser LK, Lenaerts AJ, Johnson JL, Eisenach KD, Joloba ML, et al. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD + adduct. Antimicrob Agents Chemother 2012; 56:28-35.
80. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev 2012; 44:116-126.
81. Fukino K, Sasaki Y, Hirai S, Nakamura T, Hashimoto M, Yamagishi F, Ueno K. Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 2008; 33:187-195.
82. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18:70-79.
83. Murata K, Hamada M, Sugimoto K, Nakano T. A novel mechanism for drug-induced liver failure: inhibition of histone acetylation by hydralazine derivatives. J Hepatol 2007; 46:322-329.
84. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935-952.
85. Zabost A, Brzezi?ska S, Kozi?ska M, Blachnio M, Jagodzi?ski J, Zwolska Z, Augustynowicz-Kope? E. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients. Biomed Res Int 2013; 2013:853602.
86. Eisenhut M, Thieme D, Schmid D, Fieseler S, Sachs H. Hair analysis for determination of isoniazid concentrations and acetylator phenotype during antituberculous treatment. Tuberc Res Treat 2012; 2012:327027.
87. Kiser JJ, Zhu R, D'Argenio DZ, Cotton MF, Bobat R, McSherry GD, et al. Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. Ther Drug Monit 2012; 34:446-451.
88. Bekker A, Schaaf HS, Seifart HI, Draper HR, Werely CJ, Cotton MF, Hesseling AC. The pharmacokinetics of isoniazid in low birth weight and premature infants. Antimicrob Agents Chemother 2014; 58:2229-2234.
89. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, Lee SY. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87:551-556.
90. Teixeira RL, Morato G, Cabello PH, Muniz LM, Moreira Ada S, Kritski AL, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011; 106:716-724.
91. Chamorro JG, Castagnino JP, Musella RM, Nogueras M, Aranda FM, Frías A, et al. Sex, ethnicity and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol 2013; 28:323-328.
92. Rana SV, Ola RP, Sharma SK, Arora SK, Sinha SK, Pandhi P, Singh K. Comparison between acetylator phenotype and genotype polymorphism of N-acetyltransferase-2 in tuberculosis patients. Hepatol Int 2012; 6:397-402.
93. Khalili H, Fouladdel S, Sistanizad M, Hajiabdolbaghi M, Azizi E. Association of N-acetyltransferase-2 genotypes and anti-tuberculosis induced liver injury; first case-controlled study from Iran. Curr Drug Saf 2011; 6:17-22.
94. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4:256-261.
95. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35:883-889.
96. Shimizu Y, Dobashi K, Mita Y, Endou K, Moriya S, Osano K, et al. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb) 2006; 86:374-381.
97. Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011; 6:e27810.
98. Costa GN, Magno LA, Santana CV, Konstantinovas C, Saito ST, Machado M, et al. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Mol Diagn Ther 2012; 16:241-250.
99. Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK, Silva CA, Vallinoto AC, Fernandes DC, et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis 2013; 17:499-504.
100. Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009; 10:1433-1445.
101. Lv X, Tang S, Xia Y, Zhang Y, Wu S, Yang Z, et al. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann Hepatol 2012; 11:700-707.
102. Leiro-Fernandez V, Valverde D, Vázquez-Gallardo R, Botana-Rial M, Constenla L, Agundez JA, Fernández-Villar A. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis 2011; 15:1403-1408.
103. Roy B, Ghosh SK, Sutradhar D, Sikdar N, Mazumder S, Barman S. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J Gastroenterol Hepatol 2006; 21:784-786.
104. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62:423-429.
105. Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drugmetabolising enzyme polymorphisms on the risk of anti-tuberculosis druginduced liver injury: a meta-analysis. PLoS One 2012; 7:e47769.
106. Du H, Chen X, Fang Y, Yan O, Xu H, Li L, et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep 2013; 40:3591-3596.
107. Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008; 12:994-1002.
108. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a metaanalysis. Int J Tuberc Lung Dis 2012; 16:589-595.
109. Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013; 69:1091-1101.
110. Remedyrepack Inc. Isoniazid tablet drug label. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid =8920d813-dc88-456d-8607- 47a0156a4b4b. [Accessed 5 March 2013].
111. Eon Labs, Inc. Isoniazid tablet. Available at: http://dailymed.nlm.nih. gov/dailymed/lookup.cfm?setid=1553312b-ed76-421c-a055-2579bdcf366c. [Accessed May 2014].
112. PharmGKB drug labels page for isoniazid. Available at: http://www. pharmgkb.org/drug/PA450112?tabType = tabDrugLabels. [Accessed 25 October 2013].
113. Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol 2008; 121:826-832, e825.
114. Gilroy SA, Bennett NJ. Pneumocystis pneumonia. Semin Respir Crit Care Med 2011; 32:775-782.
115. Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101:34-40.
116. Pakianathan MR, Kamarulzaman A, Ismail R, McMillan A, Scott GR. Hypersensitivity reactions to high-dose co-trimoxazole in HIV-infected Malaysian and Scottish patients. AIDS 1999; 13:1787-1788.
117. Zieli?ska E, Niewiarowski W, Bodalski J. The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children. Eur J Clin Pharmacol 1998; 54:779-785.
118. Sacco JC, Abouraya M, Motsinger-Reif A, Yale SH, McCarty CA, Trepanier LA. Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity. Pharmacogenet Genomics 2012; 22:733-740.
119. Leckband SG, Kelsoe JR, Dunnenberger HM, George AL Jr, Tran E, Berger R, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013; 94:324-328.
120. Monarch Pharmaceuticals Inc. SEPTRA (trimethoprim and sulfamethoxazole) tablet SEPTRA DS (trimethoprim and sulfamethoxazole) tablet. Available at: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=110521. [Accessed 13 June 2013].
121. Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EG, Sim E, Park BK. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000; 10:705-713.
122. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003; 55:158-165.
123. O'Neil WM, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, et al. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 2002; 42:613-619.
124. Wolkenstein P, Loriot MA, Aractingi S, Cabelguenne A, Beaune P, Chosidow O. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics 2000; 10:821-828.
125. Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer UA, Haefeli WE. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996; 60:62-67.
126. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprimsulphamethoxazole in HIV-infected patients. AIDS 1994; 8:333-337.
127. Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 2010; 66:475-485.
128. Makarova SI. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr Drug Metab 2008; 9:538-545.
129. Israili ZH, Dayton PG. Metabolism of hydralazine. Drug Metab Rev 1977; 6:283-305.
130. Cohn JN, McInnes GT, Shepherd AM. Direct-acting vasodilators. J Clin Hypertens (Greenwich) 2011; 13:690-692.
131. Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007; 18:1529-1538.
132. Arce C, Pérez-Plasencia C, González-Fierro A, de la Cruz-Hernández E, Revilla-Vázquez A, Chávez-Blanco A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006; 1:e98.
133. Candelaria M, de la Cruz-Hernandez E, Taja-Chayeb L, Perez-Cardenas E, Trejo-Becerril C, Gonzalez-Fierro A, et al. DNA methylationindependent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. PLoS One 2012; 7:e29181.
134. Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics 2008; 9:1879-1902.
135. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37:25-79.
136. Lemke LE, McQueen CA. Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine. Drug Metab Dispos 1995; 23:559-565.
137. Gonzalez-Fierro A, Vasquez-Bahena D, Taja-Chayeb L, Vidal S, Trejo-Becerril C, Pérez-Cardenas E, et al. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. Int J Clin Pharmacol Ther 2011; 49:519-524.
138. Rashid JR, Kofi T, Juma FD. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital. East Afr Med J 1992; 69:406-408.
139. Spinasse LB, Santos AR, Suffys PN, Muxfeldt ES, Salles GF. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. Pharmacogenomics 2014; 15:169-178.
140. Rowell NP, Clark K. The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status. Radiother Oncol 1990; 18:293-298.
141. Graves DA, Muir KT, Richards W, Steiger BW, Chang I, Patel B. Hydralazine dose-response curve analysis. J Pharmacokinet Biopharm 1990; 18:279-291.
142. Arbor Pharmaceuticals Inc. BIDIL (hydralazine hydrochloride and isosorbide dinitrate) tablet, film coated. Available at: http://dailymed.nlm. nih.gov/dailymed/lookup.cfm?setid= e1e63cd5-d1e4-4af5-bad5-1ad41ea46b00. [Accessed 26 March 2013].
143. Schoonen WM, Thomas SL, Somers EC, Smeeth L, Kim J, Evans S, Hall AJ. Do selected drugs increase the risk of lupus? A matched casecontrol study. Br J Clin Pharmacol 2010; 70:588-596.
144. Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011; 34:357-374.
145. Sim E, Gill EW, Sim RB. Drugs that induce systemic lupus erythematosus inhibit complement component C4. Lancet 1984; 2:422-424.
146. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010; 34:J276-J286.
147. Mazari L, Ouarzane M, Zouali M. Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus. Proc Natl Acad Sci USA 2007; 104:6317-6322.
148. Shukla V, Cuenin C, Dubey N, Herceg Z. Loss of histone acetyltransferase cofactor transformation/transcription domain-associated protein impairs liver regeneration after toxic injury. Hepatology 2011; 53:954-963.
149. Shi Y, Sun H, Bao J, Zhou P, Zhang J, Li L, Bu H. Activation of inactive hepatocytes through histone acetylation: a mechanism for functional compensation after massive loss of hepatocytes. Am J Pathol 2011; 179:1138-1147.
150. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, et al. DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. Nucleic Acids Res 2011; 39:D1035-D1041.
151. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36:D901-D906.
152. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006; 34 (Database issue): D668-D672.
153. Das KM, Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1976; 1:406-425.
154. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972; 181:555-562.
155. DrugBank: sulfasalazine DB00795. Available at: http://www.drugbank.ca/ drugs/DB00795. [Accessed 13 August 2013].
156. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, et al. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 2008; 84:95-103.
157. Ma JJ, Liu CG, Li JH, Cao XM, Sun SL, Yao X. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin Chim Acta 2009; 407:30-35.
158. Kuhn UD, Anschütz M, Schmücker K, Schug BS, Hippius M, Blume HH. Phenotyping with sulfasalazine-time dependence and relation to NAT2 pharmacogenetics. Int J Clin Pharmacol Ther 2010; 48:1-10.
159. Soejima M, Kawaguchi Y, Hara M, Kamatani N. Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis. J Rheumatol 2008; 35:724.
160. Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB. PharmGKB summary: caffeine pathway. Pharmacogenet Genomics 2012; 22:389-395.
161. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984; 17:459-464.
162. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr 2007; 21:190-200.
163. Djordjevic N, Carrillo JA, Roh HK, Karlsson S, Ueda N, Bertilsson L, Aklillu E. Comparison of N-acetyltransferase-2 enzyme genotypephenotype and xanthine oxidase enzyme activity between Swedes and Koreans. J Clin Pharmacol 2012; 52:1527-1534.
164. Djordjevic N, Carrillo JA, Ueda N, Gervasini G, Fukasawa T, Suda A, et al. N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population. J Clin Pharmacol 2011; 51:994-1003.
165. Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J, et al. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. Eur J Clin Pharmacol 2004; 60:17-21.
166. Rybak ME, Pao CI, Pfeiffer CM. Determination of urine caffeine and its metabolites by use of high-performance liquid chromatography-tandem mass spectrometry: estimating dietary caffeine exposure and metabolic phenotyping in population studies. Anal Bioanal Chem 2014; 406:771-784.
167. Rihs HP, John A, Scherenberg M, Seidel A, Brüning T. Concordance between the deduced acetylation status generated by high-speed: realtime PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. Clin Chim Acta 2007; 376:240-243.
168. Zhao B, Seow A, Lee EJ, Lee HP. Correlation between acetylation phenotype and genotype in Chinese women. Eur J Clin Pharmacol 2000; 56:689-692.
169. O'Neil WM, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW. N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 1997; 62:261-271.
170. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57:581-592.
171. Le Marchand L, Sivaraman L, Franke AA, Custer LJ, Wilkens LR, Lau AF, Cooney RV. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? Cancer Epidemiol Biomarkers Prev 1996; 5:449-455.
172. Notarianni LJ, Dobrocky P, Godlewski G, Jones RW, Bennett PN. Caffeine as a metabolic probe: NAT2 phenotyping. Br J Clin Pharmacol 1996; 41:169-173.
173. Vrtic F, Haefeli WE, Drewe J, Krahenbühl S, Wenk M. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. Br J Clin Pharmacol 2003; 55:191-198.
174. Cui X, Lu X, Hiura M, Omori H, Miyazaki W, Katoh T. Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population. Environ Health Prev Med 2013; 18:136-142.
175. Pesch B, Gawrych K, Rabstein S, Weiss T, Casjens S, Rihs HP, et al. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort. Cancer Epidemiol Biomarkers Prev 2013; 22:2055-2065.
176. Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 2014; 23:1387-1398.
177. Rothman N, Garcia-Closas M, Hein DW. Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned. Int J Epidemiol 2007; 36:23-28.
178. Wu K, Wang X, Xie Z, Liu Z, Lu Y. N-acetyltransferase 1 polymorphism and bladder cancer susceptibility: a meta-analysis of epidemiological studies. J Int Med Res 2013; 41:31-37.
179. Basma HA, Kobeissi LH, Jabbour ME, Moussa MA, Dhaini HR. CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population. Int J Mol Epidemiol Genet 2013; 4:207-217.
180. Kobeissi LH, Yassine IA, Jabbour ME, Moussa MA, Dhaini HR. Urinary bladder cancer risk factors: a Lebanese case-control study. Asian Pac J Cancer Prev 2013; 14:3205-3211.
181. Yassine IA, Kobeissi L, Jabbour ME, Dhaini HR. N-acetyltransferase 1 (NAT1) genotype: a risk factor for urinary bladder cancer in a Lebanese population. J Oncol 2012; 2012:512976.
182. Boukouvala S, Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev 2005; 37:511-564.
183. Agúndez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 2008; 9:520-531.
184. Zhang L, Xiang Z, Hao R, Li R, Zhu Y. N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case-control studies. Tumour Biol 2014; 35:3585-3595.
185. Zgheib NK, Shamseddine AA, Geryess E, Tfayli A, Bazarbachi A, Salem Z, et al. Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women. Mutat Res 2013; 747-748:40-47.
186. Fernandes MR, de Carvalho DC, dos Santos ÂK, dos Santos SE, de Assumpção PP, Burbano RM, dos Santos NP. Association of slow acetylation profile of NAT2 with breast and gastric cancer risk in Brazil. Anticancer Res 2013; 33:3683-3689.
187. Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Association of genetic polymorphisms of N-acetyltransferase 2 and susceptibility to esophageal cancer in north Indian population. Cancer Invest 2007; 25:340-346.
188. Malik MA, Upadhyay R, Modi DR, Zargar SA, Mittal B. Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir Valley. Arch Med Res 2009; 40:416-423.
189. Wang L, Tang W, Chen S, Sun Y, Fan Y, Shi Y, et al. N-acetyltransferase 2 polymorphisms and risk of esophageal cancer in a Chinese population. PLoS One 2014; 9:e87783.
190. Gibson TM, Smedby KE, Skibola CF, Hein DW, Slager SL, de Sanjose S, et al. Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes Control 2013; 24:125-134.
191. Shin A, Shrubsole MJ, Rice JM, Cai Q, Doll MA, Long J, et al. Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. Cancer Epidemiol Biomarkers Prev 2008; 17:320-329.
192. Andersen V, Holst R, Vogel U. Systematic review: diet-gene interactions and the risk of colorectal cancer. Aliment Pharmacol Ther 2013; 37:383-391.
193. Millner LM, Doll MA, Stepp MW, States JC, Hein DW. Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct. Carcinogenesis 2012; 33:348-355.
194. Sim E, Walters K, Boukouvala S. Arylamine N-acetyltransferases: from structure to function. Drug Metab Rev 2008; 40:479-510.
195. Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, et al. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 2003; 1:826-835.
196. Laurieri N, Crawford MH, Kawamura A, Westwood IM, Robinson J, Fletcher AM, et al. Small molecule colorimetric probes for specific detection of human arylamine N-acetyltransferase 1, a potential breast cancer biomarker. J Am Chem Soc 2010; 132:3238-3239.
197. Tiang JM, Butcher NJ, Cullinane C, Humbert PO, Minchin RF. RNAimediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One 2011; 6:e17031.
198. Tiang JM, Butcher NJ, Minchin RF. Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDAMB-231 breast cancer cells. Biochem Biophys Res Commun 2010; 393:95-100.
199. Russell AJ, Westwood IM, Crawford MH, Robinson J, Kawamura A, Redfield C, et al. Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2. Bioorg Med Chem 2009; 17:905-918.
200. Ragunathan N, Dairou J, Pluvinage B, Martins M, Petit E, Janel N, et al. Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition. Mol Pharmacol 2008; 73:1761-1768.
201. Lu KH, Lin KL, Hsia TC, Hung CF, Chou MC, Hsiao YM, Chung JG. Tamoxifen inhibits arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human leukemia HL-60 cells. Res Commun Mol Pathol Pharmacol 2001; 109:319-331.
202. Lee JH, Lu HF, Wang DY, Chen DR, Su CC, Chen YS, et al. Effects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cells. Res Commun Mol Pathol Pharmacol 2004; 115-116:217-233.
203. Freeman CL, Swords R, Giles FJ. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? Expert Rev Hematol 2012; 5:17-26.
204. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 2001; 29:596-600.
205. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991; 50:573-579.
206. Ratain MJ, Rosner G, Allen SL, Costanza M, Van Echo DA, Henderson IC, Schilsky RL. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol 1995; 13:741-747.
207. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 1993; 53:2304-2308.
208. Ratain MJ, Mick R, Janisch L, Berezin F, Schilsky RL, Vogelzang NJ, Kut M. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 1996; 6:93-101.
209. Ladero JM. Influence of polymorphic N-acetyltransferases on nonmalignant spontaneous disorders and on response to drugs. Curr Drug Metab 2008; 9:532-537.
210. Batra J, Ghosh B. N-acetyltransferases as markers for asthma and allergic/atopic disorders. Curr Drug Metab 2008; 9:546-553.